Please assess the completion status of the following clinical trial:

Trial Title: Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Waldenström macroglobulinemia, splenic lymphoma with villous lymphocytes (SLVL), or non-IgM lymphoplasmacytic lymphoma based on morphological and immunophenotypic criteria~  * Bone marrow should be assessed by two-color flow cytometry for the expression of the following antigens:~    * Surface Ig~   * CD19~   * CD20~   * CD5~   * CD10~   * CD23~* Previously untreated disease requiring therapeutic intervention (as judged by the primary physician), as indicated by ≥ 1 of the following:~  * Hemoglobin \< 10 g/dL~ * ANC \< 1.5 x 10\^9/L~ * Platelet count \< 150 x 10\^9/L~ * Clinical evidence of hyperviscosity in terms of neurological or ocular disturbance~* Patients with disease detected by clonal cells alone are not eligible~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Life expectancy \> 6 months~* Serum creatinine \< 200 mmol/L~* AST and ALT \< 2 times upper limit of normal~* Negative direct Coomb's test~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy~* No severe or life-threatening cardiac, pulmonary, neurological, psychiatric, or metabolic disease~* No other concurrent malignancy~* No AIDS or AIDS-related complex~* No evidence of active hepatitis C infection~PRIOR CONCURRENT THERAPY:~* Prior plasmapheresis for control of clinically significant hyperviscosity allowed~* Prior splenectomy for SLVL allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).